Celldex Therapeutics CLDX Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Celldex Therapeutics's accrued liabilities, current?
- Celldex Therapeutics (CLDX) reported accrued liabilities, current of $38.42M in Q1 2026.
- How has Celldex Therapeutics's accrued liabilities, current changed year-over-year?
- Celldex Therapeutics's accrued liabilities, current increased by 50.9% year-over-year, from $25.46M to $38.42M.
- What is the long-term trend for Celldex Therapeutics's accrued liabilities, current?
- Over 5 years (2020 to 2025), Celldex Therapeutics's accrued liabilities, current has grown at a 40.9% compound annual growth rate (CAGR), from $8.46M to $47.03M.